We report a patient with peripheral rheumatoid corneal melting who developed a corneal perforation in one eye requiring tectonic keratoplasty. Nine consecutive corneal grafts were rapidly destroyed despite systemic Tectonic keratoplasty may be required in the treatment of rheumatoid corneal melting if the anatomical integrity of the eye is threatened. However, these grafts have a high failure rate due mainly to recurrent melting.l Graft survival is enhanced by systemic immunosuppression to con-
trol the underlying rheumatoid disease? Effective immunosuppressive agents include corticosteroids, cyclophosphamide and azathioprine?-5 Pulsed intra venous immunosuppressive therapy may control disease unresponsive to oral therapy.6 Systemic immunosuppression also reduces the risk of irrever sible graft rejection. Corticosteroids, cyclosporin A and azathioprine have been employed in high-risk keratoplasty as prophylaxis against rejection?,8 HLA matching now appears to confer no additional benefit.9 Nevertheless, despite current immunosup pressive regimens, these grafts may still be subject to recurrent melting or rejection.
Anti-T-cell monoclonal antibodies (mAbs) pro vide highly specific and effective immunosuppres sion. Experimental studies have suggested their potential value in the treatment of immune mediated ocular disorders. Corneal graft survival is prolonged by peri-operative systemic mAb ther apy,lO-13 while acute rejection episodes can be reversed by intracameral mAb administration?4 Systemic mAb therapy can also suppress autoim mune scleritisl5 and uveitis.l6 There are only two reports of anti-T-cell mAbs being used to treat ocular disorders in man, to reverse acute corneal graft rejection by intracameral administrationp,l8
CAMPATH-IH is a humanised IgG l mAb that is specific for the CD52 antigen present on all lymphocytes and monocytes but absent from other cells.l9 It was created by introducing the hypervari able regions of a rat anti-CD52 mAb into a human immunoglobulin gene?O The resultant humanised mAb is less immunogenic than the rat 'parent' Eye (1995) 9, 564-569 © 1995 Royal College of Ophthalmologists mAb?l CAMPATH-1H is a highly effective immu nosuppressive agent. Its administration is followed by a prolonged peripheral blood lymphopenia with a differential effect on lymphocyte subsets.21 T-cells are predominantly affected and remain depressed for many months, with CD4+ cells taking longer to recover than CD8+ cells. B-cells are also depleted, but rapidly recover. Natural killer cells and mono cytes, however, are less susceptible to lysis by CAMPA TH -1H and their peripheral blood counts fall only transiently.
CAMPATH-1H has been used to treat refractory cases of rheumatoid arthritis21,22 and systemic vasculitisP,24 Other anti-CD 52 mAbs have proved effective in the prophylaxis25 and treatmenf6 of allograft rejection in renal transplantation. We report the use of CAMPATH-1H to treat a patient with immune-mediated corneal graft destruction that was resistant to immunosuppression with conventional agents.
CASE REPORT
A 70-year-old man with a 45-year history of seropositive rheumatoid arthritis was referred in July 1989 with progressive peripheral corneal melting in the left eye. His ocular problems had commenced in 1984 when he developed mild keratoconjunctivitis sicca. In October 1988, he developed peripheral Each graft was performed by the same surgeon (P.G.W.). The first three grafts were eccentric, while the others were all central. Organ cultured donor materiaf7 was used for the first nine grafts. Fresh donor material was used for the final graft. Topical dexamethasone 0.1 % and chloramphenicol 0.5% were administered after each graft. aMePred, intraoperative pulse of i.v. methylprednisolone (500 mg); MePred + CP, intraoperative pulse of i.v. methylprednisolone (1 g) and cyclophosphamide (500 mg); x2, pulse repeated after 48 hours. bpred, prednisolone (15 mg/day); CP, cyclophosphamide (2 mg/kg/day); CsA, cyclosporin A (3 mg/kg/day); Aza, azathioprine (1.5 mg/kg! day); Pred', prednisolone initially at high dose (60 mg/day), tapered (to 15 mg/day) over 1 week. cA full-thickness donor corneal button was sutured on the recipient lamellar bed. dThe donor material had one mismatch at each of the HLA-A, B and DR loci. tion. He was referred to Addenbrooke's Hospital for further treatment.
Tectonic keratoplasty was performed with con current systemic immunosuppression to control the rheumatoid corneal melting. His systemic rheuma toid disease was active at the time of referral (erythrocyte sedimentation rate 52 mm/h, C-reactive protein 62 mg/l and rheumatoid factor 332 IU/ml). However, despite intensive immunosuppressive ther apy, nine consecutive corneal grafts performed in the left eye were rapidly destroyed (Table I, Fig. 2) . Treatment with corticosteroids, cyclophosphamide, azathioprine and cyclosporin A each failed to prevent recurrent melting of the graft. A rejection episode was observed in one graft, comprising diffuse graft thickening and keratic precipitates. Topical and systemic corticosteroids were given but the graft subsequently melted.
In April 1993, a 14-mm corneoscleral graft was performed using CAMPATH-IH for systemic immunosuppression.
Informed consent was obtained from the patient. Fresh donor material was employed and the transplanted corneoscleral disc included limbus and perilimbal conjunctiva. CAMPATH-IH was administered as an intravenous infusion of 12 mg antibody over 4 hours given daily for 5 consecutive days, with the first dose being given 12 hours prior to surgery (total dose 60 mg anti body)?l This resulted in a profound peri-operative depletion of peripheral blood lymphocytes (Fig. 3) . Oral prednisolone (15 mg/day) and cyclosporin A (7.5 mg/kg pre-operatively, followed by 3 mg/kg/day) were also given for maintenance immunosuppres sion.
The graft was initially clear and the donor epithelium remained intact. A rejection episode developed in the fourth post-operative week consist ing of localised keratic precipitates and graft vascularisation at 7 o'clock. This was readily reversed by hourly topical dexamethasone 0.1 %. Recurrent corneal melting has not developed and there have been no further rejection episodes during 24 months follow-up (Fig. 4) . The best corrected visual acuity is 6/12. Ocular hypertension (probably steroid-related) has subsequently developed in both eyes, controlled by oral acetazolamide. Maintenance topical therapy comprises dexamethasone 0.1 % (three times daily) and frequent artificial tears. Systemic immunosuppression is gradually being reduced and currently comprises oral prednisolone (7.5 mg/day) and cyclosporin A (2 mg/kg/day -whole blood level 75 fLg/l). The peripheral blood CD4+ cell count has remained depressed (0.25 x 109/1), with a CD4/CD8 ratio of 0.29. There have been no adverse effects from this immunosuppressive regimen.
DISCUSSION
We have reported a patient with peripheral rheumatoid corneal melting who required tectonic keratoplasty. Despite intensive systemic immuno suppression, nine consecutive corneal grafts per formed in one eye were rapidly destroyed. In addition to recurrent rheumatoid melting, the later grafts were also at high risk of rejection since the recipient bed was heavily vascularised and actively infiamed?8 Rejection was observed in only one of these grafts, but may have occurred in others without being clinically evident because of concurrent melting. Graft survival was ultimately achieved by systemic immunosuppression with the anti-lympho cyte mAb, CAMPATH-IH. Corneal melting has not recurred in this graft during 24 months follow-up. A single episode of rejection did develop in the early post-operative period, but was easily reversed by topical corticosteroid.
Corneal melting results from the enzymatic degradation of stromal collagen and proteogly cans?9 The exact pathogenesis in rheumatoid disease is uncertain, but it appears to be immunolo gically mediated involving both cell-mediated and humoral mechanisms.4,30-32 Corneal graft rejection is a T-cell-mediated process that destroys epithelial, stromal and endothelial cells?3,34 Irreversible rejec tion leads to graft oedema and opacification, but is not considered to cause loss of corneal tissue per se. The later grafts performed in our patient may have been subject to both rheumatoid melting and rejection. It is possible that the rapid graft destruc tion observed resulted from the combined effect of these two disorders. For example, stromal oedema due to graft rejection could exacerbate rheumatoid melting by exposing collagen fibrils to the action of collagenases. Similarly, rheumatoid melting could precipitate rejection by inducing aberrant expression of HLA class II antigens on cells in the graft. 32 The immunosuppressive regimen employed for the final graft has achieved long-term graft survival. This may simply be due to continued systemic immuno suppression. CAMP ATH -lH therapy itself results in prolonged peripheral blood lymphopenia?l In addi tion, the patient continues to receive maintenance therapy with prednisolone and cyclosporin A. A more exciting possibility, however, is that CAM PATH-IH therapy has induced immunological tolerance to the final graft. In animal models of transplantation, anti-T-cell mAbs can induce graft tolerance even in sensitised recipients?5 Other experimental studies suggest that potent regulatory mechanisms exist which maintain the tolerant state once it has been established?6 In theory, it is therefore possible to control both allograft rejection and autoimmune disease in man by using anti-T-cell mAbs to reprogramme the immune system for tolerance?7 Whilst tolerance induction might account for the long-term survival of the final graft, this hypothesis can only be tested by withdrawal of maintenance immunosuppression with the obvious attendant risks.
We consider that CAMPATH-IH therapy was the principal factor which determined the survival of the final graft. While the immunosuppressive regimen included maintenance therapy with oral prednisolone and cyclosporin A, this background immunosuppres sion was no different from that employed unsuccess fully for previous grafts. The topical medication given after the final graft was also no different from that used previously. Transplantation of fresh limbal tissue may possibly have contributed to the success of the final graft by providing limbal stem cells, thereby promoting the establishment of a stable graft epithelium. If limbal allograft transplantation has been successful in this patient, the result may be significant in its own right since this procedure usually fails from rejection.38 CAMP A TH -lH therapy is generally well tolerated and our patient suffered no adverse effects. A reaction may develop on the first day of treatment consisting of pyrexia, rigors, nausea and occasionally systemic hypotension.21 This first-dose reaction accompanies lymphocyte destruction and is prob ably mediated by released cytokines. The prolonged lymphopenia induced by CAMPATH-IH therapy can theoretically predispose to various infections. However, this does not appear to be a prominent problem in practice. 21 Of course, conventional immunosuppressive agents such as corticosteroids, cytotoxic drugs and cyclosporin A are themselves not free of significant adverse effects.
In conclusion, mAbs show considerable promise as highly specific and effective immunosuppressive agents in the treatment of ocular disorders.
